Genentech Partners with COUR Pharmaceuticals in $940M Deal to Develop Tolerogenic Nanoparticle Therapy for Autoimmune Diseases

Dec 03, 2024 19:57 CST Updated 19:57

Cour Pharmaceuticals

Drug Developer

Genentech

Pharmaceutical R&D Manufacturer

December 3,Chicago, COUR Pharmaceuticals, a clinical-stage biotechnology company developing first-in-class disease-modifying therapies designed to induce antigen-specific tolerance for immune-mediated diseases, announced a collaboration with Roche'sGenentechReached a strategic cooperation and licensing agreement to develop and commercialize COUR's proprietary autoimmune disease tolerance nanoparticle therapeutic approach. (New Star! $105 Million Series A Financing, Backed by Roche, Pfizer, and BMS)

Under the terms of the agreement, COUR is eligible to receive $40 million in upfront and near-term milestones, as well as additional development, commercial, and net sales milestone payments potentially exceeding $900 million, along with tiered royalties on net sales.According to the cooperation agreement with Genentech, COUR is responsible for preclinical development and manufacturing technology transfer.Genentech will be responsible for clinical development, regulatory filings, and commercialization.

Dannielle Appelhans, President and CEO of COUR, stated:"Genentech has a long history of innovation, and we are excited to leverage COUR's proprietary tolerance platform（This foundational technology was licensed from Professor Steve Miller's laboratory at Northwestern University and builds upon over 30 years of immune tolerance research.）"To collaboratively develop disease-modifying therapies for autoimmune diseases. We view Genentech as an ideal partner with world-class scientific expertise, providing a unique opportunity to build on the clinical successes that COUR has achieved so far in autoimmune diseases. Through this collaboration, we believe we have the potential to make a significant impact on important patient populations."

Boris L. Zaïtra, Head of Corporate Business Development at Roche, stated:"We have a long and successful tradition of advancing innovative science and developing transformative medicines for people diagnosed with autoimmune diseases. Collaborations with innovative partners like COUR support our rigorous commitment to pioneering science in pursuit of research advances, such as novel tolerogenic nanoparticle therapies, to deliver the most impactful medicines to patients with significant unmet needs."

Follow the official account below to see the world!